Literature DB >> 2572286

Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.

Z Kelman1, M Prokocimer, S Peller, Y Kahn, G Rechavi, Y Manor, A Cohen, V Rotter.   

Abstract

Molecular structural analysis of the p53 gene in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) indicates a significant incidence of gene rearrangements in patients at either accelerated phase or blastic crisis. Southern blot analysis of genomic DNA hybridizing with either genomic or cDNA p53 specific probes indicated that 30% of the CML patients at blastic crisis phase exhibited rearrangements, mostly mapping downstream to the first non-coding exon. This is compatible with the observation that the progression of CML from the chronic to the acute phase involves frequent aberrations in chromosome 17, to which the p53 oncogene has been mapped. Therefore, we suggest that one of the pathways of development of CML to the acute phase is associated with aberrations in the p53 nuclear oncogene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572286

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

2.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.

Authors:  G Shaulsky; N Goldfinger; A Ben-Ze'ev; V Rotter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

3.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

5.  A DNA binding domain is contained in the C-terminus of wild type p53 protein.

Authors:  O S Foord; P Bhattacharya; Z Reich; V Rotter
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

6.  Involvement of wild-type p53 in pre-B-cell differentiation in vitro.

Authors:  G Shaulsky; N Goldfinger; A Peled; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

Review 7.  The p53 tumor suppressor protein regulates hematopoietic stem cell fate.

Authors:  Takashi Asai; Yan Liu; Narae Bae; Stephen D Nimer
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

8.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.

Authors:  J Yeargin; J Cheng; A L Yu; R Gjerset; M Bogart; M Haas
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.